Andrew Tsai
Stock Analyst at Jefferies
(0.19)
# 4,090
Out of 4,829 analysts
17
Total ratings
20%
Success rate
-35.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $107.76 | +85.60% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $19.30 | +39.90% | 2 | Mar 19, 2025 | |
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $29 | $6.99 | +314.88% | 1 | Dec 18, 2024 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $165 | $36.27 | +354.92% | 1 | Oct 21, 2024 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.42 | +2,998.93% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $10.23 | +242.13% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $2.22 | +1,386.49% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.26 | +563.72% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.70 | +327.96% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $0.25 | +1,079.71% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.46 | +713.01% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.39 | +1,842.45% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $35.02 | -34.32% | 1 | Jun 1, 2020 |
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $107.76
Upside: +85.60%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $19.30
Upside: +39.90%
Rocket Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $29
Current: $6.99
Upside: +314.88%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $36.27
Upside: +354.92%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.42
Upside: +2,998.93%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $10.23
Upside: +242.13%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $2.22
Upside: +1,386.49%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.26
Upside: +563.72%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.70
Upside: +327.96%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.25
Upside: +1,079.71%
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $2.46
Upside: +713.01%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $1.39
Upside: +1,842.45%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $35.02
Upside: -34.32%